• linkedin
  • Increase Font
  • Sharebar

    New data: Hospital readmission among NVAF hospitalized patients treated with new oral anticoagulants

    Data from a real-world analysis provided an early view of hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients treated with new oral anticoagulants (NOACs).

    In a retrospective, observational cohort study presented at the 27th annual meeting and expo of the Academy of Managed Care Pharmacy in San Diego, provided an early view of readmissions within 1 month following an initial hospitalization in a Premier hospital for patients with a primary or secondary discharge diagnosis of NVAF treated with dabigatran, rivaroxaban or apixaban.

    Related: First-line stroke treatment may be given by paramedics

    The study found that treatment of NVAF patients with apixaban was associated with lower hospital cost, shorter average length of stay and lower likelihood of hospital readmissions within 1 month following hospitalization, compared to treatment with rivaroxaban. Similar trends were observed when compared with dabigatran, though not statistically significant.

    Related: What is new in the anticoagulant antidote market?

    In the study, between January 1, 2012, and February 28, 2014, patients aged 18 years and older with a primary or secondary hospital discharge diagnosis of atrial fibrillation who received apixaban, dabigatran or rivaroxaban at any time during the hospitalization were identified from the Premier Hospital database. Patients were grouped into 3 cohorts depending on which NOAC they received during hospitalization. Patient demographics and clinical characteristics were evaluated. Multivariable logistic regression was used to identify predictors of hospital readmissions occurring within 1 month after the index hospitalization and multivariable generalized linear models were used to examine the associations of hospital length of stay and the costs of hospital readmissions within 1 month after the hospitalization with the treatment of NVAF patients, using dabigatran, rivaroxaban or apixaban, while adjusting for key patient and hospital characteristics.

    NEXT: NVAF patients had varying baseline characteristics

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available